Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of pharmaceutical composition containing mesenchymal stem cell exosome to treatment of diseases

A technology of mesenchymal stem cells and compositions, applied in the field of biopharmaceuticals, can solve the problems of difficult to obtain curative effect, limited improvement of pulmonary fibrosis, high production and management costs

Active Publication Date: 2021-02-09
GUANGDONG CELL BIOTECHNOLOGY CO LTD
View PDF7 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Following inflammatory factors, mesenchymal stem cells are also used to treat pulmonary fibrosis, but the direct use of mesenchymal stem cells requires the cultivation of a large number of primary cells, which is cumbersome and requires high production and management costs. Due to the unknown composition of the culture substrate used in the cell culture process, the injection of exogenous allogeneic stem cells leads to graft-versus-host reactions, so its safety and stability have also been questioned, which is not conducive to clinical application and promotion. Mesenchymal stem cell exosomes have been used to treat pulmonary fibrosis, and some positive effects have been achieved, such as Yang Jing et al. 2020, 40(7): 988-994) Using human umbilical cord mesenchymal stem cell exosomes (hUCMSC-EXOs, alleviates lung fibrosis in mice by inhibiting epithelial-mesenchymal transition activated by TGF-β1 / Smad2 / 3 signaling pathway The degree of cell culture, Zhang Anguo (Study on the efficacy and mechanism of bone marrow mesenchymal stem cell-derived exosomes in inhibiting silica-induced pulmonary fibrosis, University of Jinan, master's thesis, 2019) using bone marrow mesenchymal stem cells (bone marrow mesenchymal stem cells , BMSCs) exosomes intervene in silica-induced pulmonary fibrosis, which can improve the lung coefficient of rats and reduce the expression level of pro-fibrotic factor TGF-β1
However, due to the multidirectional differentiation of mesenchymal stem cells, the targeting of treatment is not high, and side effects are likely to be caused, so it is still difficult to obtain satisfactory curative effect by using mesenchymal stem cells or their exosomes in the treatment of pulmonary fibrosis. limited improvement

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of pharmaceutical composition containing mesenchymal stem cell exosome to treatment of diseases
  • Application of pharmaceutical composition containing mesenchymal stem cell exosome to treatment of diseases
  • Application of pharmaceutical composition containing mesenchymal stem cell exosome to treatment of diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Example 1 Preparation of single domain antibody targeting IL-13

[0037] Human IL-13 protein was used to immunize alpacas, and a single domain antibody targeting IL-13 was screened through a phage display library. The specific methods included:

[0038] (1) Alpaca antigen immunization.

[0039] Mix 100 μg of human IL-13 protein with 100 μL of Freund’s complete adjuvant to make an emulsified mixture, select healthy adult dromedary camels, and use the emulsified mixture to immunize alpacas by subcutaneous injection at multiple points on the back. The first two immunizations Freund's complete adjuvant was used, and the subsequent immunization was enhanced with an emulsified mixture of Freund's incomplete adjuvant and human IL-13 protein. A total of 8-10 immunizations were performed, and the immunization interval was 2 weeks. One week after each immunization, collect 100mL of peripheral blood, detect the titer of antiserum by ELISA, coat the detection plate with human IL-1...

Embodiment 2

[0052] Example 2 Isolation, culture and exosome acquisition of human umbilical cord MSCs

[0053] 2.1 Isolation and culture of human umbilical cord MSCs

[0054] (1) Collect fresh umbilical cords in the aseptic environment of the operating room, and quickly place the whole umbilical cord in a sterile PBS solution containing 0.5% penicillin and 0.5% streptomycin sulfate;

[0055] (2) In the biological safety cabinet, take out the umbilical cord tissue and place it in sterile PBS solution, rinse the umbilical cord repeatedly to remove the remaining blood and other impurities;

[0056] (3) Cut the umbilical cord into several sections, cut it longitudinally, and remove two umbilical arteries and one umbilical vein;

[0057] (4) Cut the umbilical cord to about 1mm with sterile surgical scissors 3 The size of the tissue block, the obtained tissue block was filtered with a 200-mesh filter to remove smaller tissue debris and cell debris;

[0058] (5) Spread the above tissue blocks ...

Embodiment 3

[0067] Example 3 The co-culture of human umbilical cord MSCs and A549 cells and the acquisition of exosomes

[0068] 3.1 Co-culture of human umbilical cord MSCs and A549 cells

[0069]The co-culture of human umbilical cord MSCs and A549 cells is carried out in a Transwell culture chamber. The bottom of the culture chamber is equipped with a semi-permeable membrane, which allows the exchange of nutrients, but the cells cannot pass through.

[0070] (1) Take A549 alveolar epithelial cells preserved in liquid nitrogen (preserved in our laboratory), revive them quickly in warm water, then add RPMI1640 medium, mix well, collect cells by centrifugation at 2000 rpm for 5 min, and wash with fresh medium for 3- 5 times, then add RPMI1640 containing 10% FBS and culture at 37°C, 5% CO 2 Cultivate 3-5 passages under certain conditions in order to fully activate A549 cells;

[0071] (2) As described in Section 2.1, culture human umbilical cord MSCs and pass them down to 3-5 generations; ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
The average diameteraaaaaaaaaa
Diameteraaaaaaaaaa
Login to View More

Abstract

The invention belongs to the technical field of biological pharmacy, and particularly relates to an application of a pharmaceutical composition containing mesenchymal stem cell to in treatment of diseases. The pharmaceutical composition contains a single-domain antibody and the mesenchymal stem cell exosome, can be used for treating pulmonary fibrosis, can significantly improve a lung tissue system, repair lung tissue damage and reduce inflammatory response, and generates synergistic effects.

Description

technical field [0001] The invention belongs to the field of biopharmaceuticals, and in particular relates to the application of a pharmaceutical composition containing mesenchymal stem cell exosomes in treating diseases. Background technique [0002] Fibrosis is a chronic progressive disease characterized by tissue fibrosis. Human organs are composed of parenchyma and interstitium. The parenchyma refers to the main structure and functional cells of the organ, which perform the main physiological functions of the organ, while the interstitium refers to the main structure and functional cells of the organ. The stroma is composed of interstitial cells and extracellular matrix, which mainly plays the role of mechanical support and connection. When the organ tissue is damaged or other abnormal physiological signals, it may cause a large amount of interstitial fibrous connective tissue to proliferate, destroying the original normal structure of the organ, resulting in Organ fibro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/24A61K39/395A61P11/00A61P1/16A61P13/12A61P17/00A61K35/28
CPCA61K35/28A61K39/39533A61P1/16A61P11/00A61P13/12A61P17/00C07K16/244C07K2317/565C07K2317/569C07K2317/92A61K2300/00
Inventor 张海涛王青
Owner GUANGDONG CELL BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com